Impaired High-Density Lipoprotein Function in Patients With Heart Failure.
cholesterol efflux
functionality
high‐density lipoprotein
outcome
proteome
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
04 05 2021
04 05 2021
Historique:
pubmed:
20
4
2021
medline:
26
10
2021
entrez:
19
4
2021
Statut:
ppublish
Résumé
Background We recently showed that, in patients with heart failure, lower high-density lipoprotein (HDL) cholesterol concentration was a strong predictor of death or hospitalization for heart failure. In a follow-up study, we suggested that this association could be partly explained by HDL proteome composition. However, whether the emerging concept of HDL function contributes to the prognosis of patients with heart failure has not been addressed. Methods and Results We measured 3 key protective HDL function metrics, namely, cholesterol efflux, antioxidative capacity, and anti-inflammatory capacity, at baseline and after 9 months in 446 randomly selected patients with heart failure from BIOSTAT-CHF (A Systems Biology Study to Tailored Treatment in Chronic Heart Failure). Additionally, the relationship between HDL functionality and HDL proteome composition was determined in 86 patients with heart failure. From baseline to 9 months, HDL cholesterol concentrations were unchanged, but HDL cholesterol efflux and anti-inflammatory capacity declined (both
Identifiants
pubmed: 33870728
doi: 10.1161/JAHA.120.019123
pmc: PMC8200730
doi:
Substances chimiques
Biomarkers
0
Lipoproteins, HDL
0
Banques de données
EudraCT
['2010‐020808‐29']
Types de publication
Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e019123Références
J Heart Lung Transplant. 2009 Sep;28(9):876-80
pubmed: 19716038
Circ Res. 2013 Dec 6;113(12):1345-55
pubmed: 24055733
J Am Heart Assoc. 2016 Dec 21;5(12):
pubmed: 28003247
Eur J Heart Fail. 2013 Nov;15(11):1215-9
pubmed: 23709232
Cell Metab. 2016 Mar 8;23(3):405-12
pubmed: 26853751
J Am Coll Cardiol. 2019 Jan 22;73(2):177-186
pubmed: 30654890
Arterioscler Thromb Vasc Biol. 2019 Sep;39(9):1874-1883
pubmed: 31315436
PLoS One. 2016 Jun 15;11(6):e0157507
pubmed: 27304214
Handb Exp Pharmacol. 2015;224:527-65
pubmed: 25523001
J Am Heart Assoc. 2021 May 4;10(9):e019123
pubmed: 33870728
Expert Rev Proteomics. 2019 Sep;16(9):749-760
pubmed: 31382838
Handb Exp Pharmacol. 2015;224:3-51
pubmed: 25522985
Circ Heart Fail. 2011 Jan;4(1):59-64
pubmed: 21062973
Eur J Heart Fail. 2016 Jun;18(6):716-26
pubmed: 27126231
Eur J Heart Fail. 2009 Mar;11(3):281-91
pubmed: 19168876
N Engl J Med. 2011 Jan 13;364(2):127-35
pubmed: 21226578
Eur J Heart Fail. 2018 Feb;20(2):260-267
pubmed: 29251807
Int J Cardiol. 2018 Feb 15;253:84-90
pubmed: 29306478
Am J Cardiol. 2013 Dec 1;112(11):1770-7
pubmed: 24050409
Eur J Heart Fail. 2017 Jun;19(6):748-755
pubmed: 28176482
J Lipid Res. 2013 Oct;54(10):2575-85
pubmed: 23434634
Lancet Diabetes Endocrinol. 2015 Jul;3(7):507-13
pubmed: 26025389
J Card Fail. 2007 May;13(4):247-53
pubmed: 17517342
N Engl J Med. 2014 Dec 18;371(25):2383-93
pubmed: 25404125
J Am Coll Cardiol. 2018 Jan 30;71(4):386-398
pubmed: 29389354
Int J Clin Pract. 2005 Jan;59(1):25-30
pubmed: 15707460
Am J Physiol Endocrinol Metab. 2016 Jan 1;310(1):E1-E14
pubmed: 26530157
Eur J Heart Fail. 2017 May;19(5):627-634
pubmed: 28247565
Nat Rev Cardiol. 2016 Jan;13(1):28-35
pubmed: 26370473
J Am Soc Nephrol. 2018 May;29(5):1356-1371
pubmed: 29472417
J Clin Lipidol. 2016 Nov - Dec;10(6):1318-1328
pubmed: 27919348
Biomark Med. 2013 Jun;7(3):457-72
pubmed: 23734809
Eur J Heart Fail. 2008 Oct;10(10):933-89
pubmed: 18826876
Eur Heart J. 2017 Jun 21;38(24):1883-1890
pubmed: 28329163
Circulation. 2009 Dec 8;120(23):2345-51
pubmed: 19933936
J Am Soc Nephrol. 2017 Mar;28(3):769-775
pubmed: 27612996